Tim Craven, Insamo CEO
February 21, 2024 06:00 AM ESTUpdated 06:34 AM
Financing
Startups

Ex­clu­sive: Dupix­ent in a pill? Start­up In­samo will try to turn block­buster bi­o­log­ics in­to orals

Andrew Dunn

Senior Biopharma Correspondent

A new biotech start­up launched Wednes­day to ad­vance a “Goldilocks” ther­a­peu­tic modal­i­ty that could turn some of the in­dus­try’s most lu­cra­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times